Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions
Commitment to partnership and joint innovation for cell and gene therapies
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Commitment to partnership and joint innovation for cell and gene therapies
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione commitment to setting SBTs in line with the Paris Agreement
Pharmaceutical Technology, 2 Junho 2021
Hovione, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform.
Outsourced Pharma, April 2023